Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV)
Health Care · Biotechnology · US
$6.77
-2.45% today · +147.0% 1Y
Artiva Biotherapeutics, Inc. (NasdaqGM: ARTV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $339.30M and employs 115 people.
Over the last twelve months the share price has gained 147.0%, trading between 2.71 and 14.53.
Tweenvest scores Artiva Biotherapeutics, Inc. across four factors: quality 38/100, value 59/100. Its strongest factor is value.
ARTV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $339.30M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.21
- Dividend yield
- —
- Beta (5Y)
- 2.41
- 52-week high
- $14.53
- 52-week low
- $2.71
- Avg volume (3M)
- —
- Shares outstanding
- 48.89M
- Employees
- 115
- Next earnings
- —
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
- ISIN
- US04317A1079
- Founded
- 2019
- Listed since
- Jul 19, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Surrozen, Inc.NasdaqCM: SRZN | $348.96M | $24.76 | -16.60% |
| BioNote, Inc.KOSE: A377740 | $348.29M | ₩4,640.00 | -1.28% |
| Jiangsu Recbio Technology Co., Ltd.SEHK: 2179 | $347.01M | HK$4.42 | +0.23% |
| ROKIT Healthcare Inc.KOSDAQ: A376900 | $346.80M | ₩26,850.00 | -3.24% |
| Agenus Inc.NasdaqCM: AGEN | $334.50M | $7.43 | -3.13% |
| Indaptus Therapeutics, Inc.NasdaqCM: INDP | $334.44M | $2.44 | -2.79% |
| GC Corp.KOSE: A005250 | $329.56M | ₩9,750.00 | +0.72% |
| 3-D Matrix, Ltd.TSE: 7777 | $328.96M | ¥407.00 | -3.10% |
Figures last refreshed Oct 11, 2026.